Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives $14.94 Consensus PT from Brokerages

Terns Pharmaceuticals, Inc. (NASDAQ:TERN – Get Free Report) has earned a consensus rating of “Moderate Buy” from the eight brokerages that are covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month price objective […]

Related Keywords

,Affinity Asset Advisors ,Terns Pharmaceuticals ,Terns Pharmaceuticals Price Performance ,Analyst Recommendations For Terns Pharmaceuticals ,Terns Pharmaceuticals Company Profile ,Vivo Opportunity Llc ,News Ratings For Terns Pharmaceuticals Daily ,Nasdaq ,Insider Activity At Terns Pharmaceuticals ,Terns Pharmaceuticals Inc ,Get Free Report ,Vivo Opportunity ,Fire Capital ,Asset Advisors ,Get Free ,Terns Pharmaceuticals Daily ,